Matakina Technology

“Breast cancer detection and diagnosis has been subjective, qualitative, inaccurate and too tuned for an “average individual” for too long. Taking a best of breed approach from technology developed by world-class innovators, Matakina’s mission is to seize the opportunity presented by digital imaging to revolutionise breast imaging so that breast cancer can be detected earlier, diagnosed more accurately and treated more effectively through tailored screening pathways.

Matakina’s patent pending, platform technology is able to convert any digital breast mammogram into quantitative numbers in which the actual breast tissue properties are characterised and differentiated, completely removing the imaging conditions, such as exposure time.”

UPDATE:

In October 2010: Matakina announced that it had attained FDA (US Food and Drug Administration) clearance to start marketing its revolutionary Volpara breast imaging software into the $1Bn, US breast imaging market.

The Volpara product automatically computes breast density from the standard breast x-rays taken when a woman attends breast screening. Breast density has been linked to the sensitivity of x-rays for the detection of breast cancer, the risk of a woman developing breast cancer, the risk of recurrence of breast cancer after surgery, and the use of certain drugs.

Matakina’s CEO, Dr Ralph Highnam, says “Volpara will improve the radiologist’s understanding of breast composition and will help them select the right imaging modalities and procedures to ensure that each and every woman is screened in the most appropriate manner.

He said they now have trials underway of Volpara right across the globe and it’s great that the FDA has now recognised Volpara as being safe and effective, so that they can begin helping radiologists help women.”